The PML gene is not involved in the regulation of MHC class I expression in human cell lines

Blood

Volumn 101, Issue 9, 2003, Pages 3514-3519

  Bruno, Silvia ^a   Ghiotto, Fabio ^b   Fais, Franco ^b   Fagioli, Marta ^b   Luzi, Lucilla ^b   Pelicci, Pier Giuseppe ^b   Grossi, Carlo Enrico ^b   Ciccone, Ermanno ^b  

^a Department of Experimental Medicine   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; RNA; HLA ANTIGEN; HYBRID PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PML PROTEIN, HUMAN; PML PROTEIN, MOUSE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CELL LINE; CELL NUCLEUS INCLUSION BODY; CYTOPLASM; DOWN REGULATION; EMBRYO; EXON; FEMALE; GENE CONSTRUCT; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; UPREGULATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL ORGANELLE; CYTOLOGY; DOMINANT GENE; FLOW CYTOMETRY; GENE; GENETICS; HELA CELL; KIDNEY; METABOLISM; MOLECULAR GENETICS; MUTATION; NEUROBLASTOMA; PATHOLOGY; PHYSIOLOGY; PRENATAL DEVELOPMENT; RNA INTERFERENCE; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CYTOPLASM; EXONS; FLOW CYTOMETRY; GENES, DOMINANT; GENES, MHC CLASS I; HELA CELLS; HLA ANTIGENS; HUMANS; INTERFERON TYPE II; KIDNEY; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; ORGANELLES; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037866466     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3335     Document Type: Article

References (33)

1. DeThé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
2. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165-170.
3. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 2001;20:7223-7233.
4. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML/RAR in acute promyelocytic leukemia cells. Cell. 1994;76:345-356.
5. Koken MH, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a retinoic-acid reversible fashion. EMBO J. 1994;13:1073-1083.
6. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2:E85-E90.
7. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. Embo J. 2002;21:3358-3369.
8. Pearson M, Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene. 2001;20:7250-7256.
9. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-1551.
10. Grignani FR, Testa U, Rogaia D, et al. Effects on differentiation by the promyelocytic leukemia PML/RARa protein depend on the fusion of the PML protein-dimerization and RARa DNA binding domains. EMBO J. 1996;15:4949-4958.
11. Rego E, Wang Z-G, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med. 2001;23:521-529.
12. Grignani F, Valtieri M, Gabbianelli M, et al. PML/RARa fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood. 2000;96:1531-1537.
13. Alcalay M, Tomassoni L, Colombo E, et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol. 1998;18:1084-1093.
14. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet. 1998;20:259-265.
15. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000;406:207-210.
16. Zhong BS, Salomoni P, Ronchetti S, Ruggero D, Pandolfi PP. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med. 2000;191:631-640.
17. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 2002;21:3358-3369.
18. Zheng P, Guo Y, Niu Q, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature. 1998;396:373-376.
19. Larghero J, Zassadowski F, Rousselot P, Padua RA, Degos L, Chomienne C. Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens. Leukemia. 1999;13:1295-1296.
20. Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia. 1999;13:1175-1187.
21. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
22. Fagioli M, Alcalay M, Pandolfi PP, et al. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene. 1992;7:1083-1091.
23. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001;9:2140-2151.
24. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acid Res. 1990;18:3587-3596.
25. Pandolfi PP, Grignani F, Alcalay M, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene. 1991;6:1285-1292.
26. Flenghi L, Fagioli M, Tomassoni L, et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood. 1995;85:1871-1880.
27. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nature Rev Genet. 2001;2:110-119.
28. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15:188-200.
29. Lavau C, Marchio A, Fagioli M, et al. The acute promyelocytic leukemia-associated PML gene is induced by interferon. Oncogene. 1995;11:871-876.
30. Chan JY, Meng CL, To KF, et al. Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. Eur J Cancer. 2002;38:1600-1606.
31. Zhang P, Chin W, Chow LT, et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer. 2000;85:599-605.
32. Tian XX, Chan JY, Pang JC, et al. Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor. Br J Cancer. 1999;81:994-1001.
33. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20:266-272.